This website is for UK Healthcare Professionals only

Resources

For healthcare professionals

BOTOX® Nurse-led Service Video

In this video, Julia Taylor, Consultant Nurse in Urology at Salford Royal NHS Foundation Trust, discusses the development and benefits of a nurse-led BOTOX® urology service.


Steve Foley talking head: How to consent a patient for BOTOX® (botulinum toxin type A) treatment

This video has been developed to support healthcare professionals in their understanding of the information that should be provided to a patient who may require BOTOX® treatment for OAB.

Stephen Foley, Consultant Urological Surgeon at the Royal Berkshire Hospital in Reading, discusses how he consents a patient for treatment as well as the key information he communicates to patients about BOTOX® treatment for OAB.

To view this talking head, please submit your details on the Contact Us page and tick Steve Foley talking head: How to consent a patient for BOTOX® (botulinum toxin type A) treatment.


Steve Foley talking head: Discussing the need to self-catheterise following BOTOX® (botulinum toxin type A) treatment

This video has been developed to support healthcare professionals in their understanding of which patients may be required to learn self-catheterisation following BOTOX® treatment for OAB.

Stephen Foley, Consultant Urological Surgeon at the Royal Berkshire Hospital in Reading, discusses his clinical approach to the topic of self-catheterisation and how to explain potential need of self-catheterisation to patients in some cases.

To view this talking head, please submit your details on the Contact Us page and tick Steve Foley talking head: Discussing the need to self-catheterise following BOTOX® (botulinum toxin type A) treatment.


EMBARK Study Clinical Summary

This clinical summary provides information on the EMBARK Phase III clinical study for BOTOX® in patients with OAB. It contains an overview of the study design, the key primary and secondary endpoints, along with an overview of the results and conclusions

If you are interested in discussing this clinical summary further, please submit your details on the Contact Us page. Tick EMBARK Study Clinical Summary and a member of the AbbVie team will be in contact with you.


DIGNITY Study Clinical Summary

This clinical summary provides information on the DIGNITY Phase III clinical studies for BOTOX® in patients with NDO. It contains an overview of the study design, the key primary and secondary endpoints, along with overview of the results and conclusions.

If you are interested in discussing this clinical summary further, please submit your details on the Contact Us page. Tick DIGNITY Study Clinical Summary and a member of the AbbVie team will be in contact with you.


Resources for your patients

A patient guide for BOTOX® (botulinum toxin type A): overactive bladder

To support your patients with OAB that have been prescribed BOTOX®, this guide provides information on how BOTOX® works, what patients can expect before and after treatment and any potential side-effects of BOTOX® treatment.

The information in this guide does not replace the Patient Information Leaflet that is included with the prescribed medication.

To receive a copy of this guide, please submit your details on the Contact Us page and tick A patient guide for BOTOX® (botulinum toxin type A): overactive bladder.


A patient guide for BOTOX® (botulinum toxin type A): neurogenic detrusor overactivity 

To support your patients with NDO that have been prescribed BOTOX®, this guide provides information on how BOTOX® works, what patients can expect before and after treatment and any potential side-effects of BOTOX® treatment.

The information in this guide does not replace the Patient Information Leaflet that is included with the prescribed medication.

To receive a copy of this guide, please submit your details on the Contact Us page and tick A patient guide for BOTOX® (botulinum toxin type A): neurogenic detrusor overactivity.

NDO: neurogenic detrusor overactivity; OAB: overactive bladder.

BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency; neurogenic detrusor overactivity with urinary incontinence due to subcervical spinal cord injury (traumatic or non-traumatic), or multiple sclerosis.5

 

References

  1. Allergan. Data on file. INT/0423/2016
  2. Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
  3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
  4. Data on File UK-BTX-230044
  5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed August 2023

Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

Date of preparation: August 2023. UK-BUO-230063.